Studies have discovered that the mechanism of tumor-acquired drug resistance may be related to mutations in the IFN-γ signaling pathway, changes in target antigens, and secondary changes in the molecular structure of human leukocyte antigen 1, which may be related to the loss of antigen expression or antigen presentation function. This evidence concerns the gene IFNG and neoplasm.